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CASE LETTERSFig 1. Gingival hyperplasia. A, Marked gingival enlarge-
ment during vemurafenib treatment. B, Rapid resolution of
gingival hyperplasia after cessation of vemurafenib.Vemurafenib-associated gingival hyperplasia
in patient with metastatic melanoma
To the Editor: Targeted inhibition of activated v-raf
murine sarcoma viral oncogene homolog B (BRAF), a
driver in a substantial proportion of melanomas, leads
to rapid and dramatic clinical responses and improved
survival in patients with metastatic melanomas (84% vs
64% 6-month survival).1 However, this remarkable
efficacy, exemplified by vemurafenib, the first Food
and Drug Administrationeapproved targeted BRAF
inhibitor, is accompanied by specific toxicities. The
most prominent side effect of vemurafenib both in
preapproval clinical trials and postmarketing surveil-
lance is the development of keratoacanthoma-like
squamous cell carcinomas, induced by paradoxical
activation of mitogen-activated protein kinase pathway
in cells harboring retrovirus-associated sequence (RAS)
mutations, such as keratinocytes on sun-damaged
skin.1,2 Other side effects possibly also representing
‘‘RASopathic’’ effects of vemurafenib include: keratosis
pilaris, acanthopapillomas, plantar hyperkeratosis,
ultraviolet Aedependent photosensitivity, maculopap-
ular exanthema, pruritus, folliculitis, burning feet,
alopecia, curly hair, nail changes, and melanomas.3
To our knowledge, we describe the first case of
vemurafenib-induced gingival hyperplasia.
A 29-year-old woman with a history of metastatic
melanoma presented to our clinic in 2011 after
having developed many subcutaneous metastases
with sequential therapy with radiation followed by
paclitaxel and carboplatin. Biopsy specimen and
polymerase chain reaction analysis of one of the
nodules showed a BRAF V600E mutation and the
patient subsequently started vemurafenib. After 2
months of therapy, the patient began to develop
keratoacanthomas, acanthopapillomas, xerosis, and
gastrointestinal distress. None of the side effects
were dose-limiting and the patient continued on
vemurafenib. After 3 months of therapy, the patient
noted severe gum hyperplasia with bleeding,
swelling, and pain (Fig 1, A). Multiple cultures
were unremarkable and the hyperplasia was
refractory to topical steroids, antifungals, and
antibacterials. Because of disease progression,
vemurafenib was stopped in favor of ipilimumab.
Within 1 month of discontinuing vemurafenib, all of
the drug-specific side effects, including the gingival
hyperplasia, resolved (Fig 1, B). Unfortunately,
because of accelerated disease our patient died
shortly after starting ipilimumab.J AM ACAD DERMATOL
Open access under CC BY-NC-ND license.Our patient represents the first described case
of vemurafenib-induced gingival hyperplasia. The
refractory nature of the hyperplasia while on vemur-
afenib and quick resolution with drug cessation
implicate vemurafenib treatment as a causative event.
Rinderknecht et al3 argue that activation of germline
mutations likely lead to unique toxicities. We can use
the germline RASopathies as guidance for possible
side effects of RAS/mitogen-activated protein kinase
activation. Interestingly, son of sevenless homolog 1
mutations result in the activation of the RAS/mitogen-
activated protein kinase pathway and are seen in
Noonan syndrome4 (OnlineMendelian Inheritance in
Man: 610733) and hereditary gingival fibromatosis 1
(Online Mendelian Inheritance in Man: 135300).4,5
Noonan syndrome 4 is characterized by congenital
anomalies and ectodermal changes: curly hair, kera-
tosis pilaris, and hyperkeratosis skin.4 Hereditary
gingival fibromatosis 1 is characterized bymild hyper-
trichosis, gingival fibromatosis, and fibro-osseous
dysplasia.5 Therefore, it seems both biologically
plausible and clinically supported that our patient’s
gingival hyperplasia may represent yet another
RASopathic side effect of vemurafenib therapy. This
and other documented side effects of vemurafenib
further illustrate the importance of recognizing andNOVEMBER 2014 e205
Fig 1. Plaque-type penile syringoma. Multiple, skin-
colored, discrete, firmpapules coalescing into a large, thick
plaque on the proximal aspect of the dorsal penile shaft.
Fig 2. Syringoma. A basaloid ductal proliferation
set almost entirely in a dense sclerotic stroma extending
into the deep reticular dermis. (Hematoxylin-eosin stain.)
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for improved and more effective patient treatment.
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Plaque-like syringoma with involvement of
deep reticular dermis
To the Editor: A healthy 28-year-old man presented
with an asymptomatic eruption on the penile shaft
for 5 years. Physical examination demonstrated
multiple 5- to 8-mm, skin-colored, discrete papules
coalescing into a plaque on the proximal aspect of
the dorsal penile shaft (Fig 1). A 4-mm punch biopsy
specimen demonstrated a basaloid ductal prolifera-
tion set almost entirely in a dense sclerotic stroma
extending into the deep reticular dermis. The ducts
were lined by 2 rows of epithelial cells with a bulging
outer layer to create a comma-shaped tail (Fig 2). The
clinical and histopathologic findings were consistent
with a plaque-type syringoma with deep extension.
Syringomas are benign adnexal neoplasms.
Eccrine versus apocrine differentiation is still debat-
able as both variants are reported in the literature.
From the histologic perspective, the main differential
diagnosis in our case included desmoplastictrichoepithelioma, infiltrating/morpheaform basal
cell carcinoma, microcystic adnexal carcinoma
(MAC), and syringomatous carcinoma. Despite the
extension into the deep reticular dermis that abutted
subcutaneous tissue, the anatomic location of the
lesion, the lack of infiltrative growth, highlighted
by the confinement of the proliferation to the
accompanying dense sclerotic stroma, and the lack
of perineural growth distinguished it from MAC,
desmoplastic trichoepithelioma, and infiltrating
basal cell carcinoma. Our case demonstrated
follicular induction, but there was no evidence of
well-differentiated follicular differentiation within
the cystic spaces, which is observed in MAC. MAC
is also characterized by bland cytology and low or
absent mitotic index, but deep and extensive
infiltration with possible perineural involvement is
